Pharmacies in England to prescribe more medication from autumn

Pharmacies in England to prescribe more – Starting this autumn, pharmacies across England will see an expansion in their prescribing capabilities, part of a broader initiative aimed at accelerating healthcare delivery and reducing the burden on general practitioner (GP) practices and hospitals. The move is backed by a £340 million investment, which will add five new conditions to the list of ailments pharmacists can currently manage under the Pharmacy First scheme. While the specific additions have not yet been disclosed, the government has emphasized the potential benefits of this expansion for patients and healthcare providers alike.

Expanded Prescribing Authority

The Pharmacy First scheme, introduced in 2024, already enables pharmacists to treat a range of common health issues, including sore throats, ear infections, sinusitis, shingles, impetigo, bite-related infections, and urinary tract infections. Under this model, patients can access advice, over-the-counter treatments, and prescription-only medications without needing to visit a GP. The scheme also extends to eye, ear, oral, and dental care, as well as treatment for digestive problems.

This autumn marks a significant step forward, with the addition of five new ailments to the prescribing list. The change is expected to further streamline care by allowing pharmacists to address more health concerns directly, thereby reducing the number of consultations required at GP surgeries. The Department of Health and Social Care highlighted that over 3.3 million consultations have already been conducted under the scheme between March 2025 and February 2026, underscoring its growing role in the NHS.

Health Minister Stephen Kinnock praised the initiative, stating that the government is “making the most of our highly skilled pharmacists” while improving access to essential services. He emphasized that independent prescribing would “ease pressures on GPs, cut unnecessary red tape, and help patients get the right care closer to home.” The minister’s comments reflect a strategic shift toward leveraging pharmacists’ expertise to enhance frontline healthcare provision.

Funding Concerns

Despite the promising expansion, the National Pharmacy Association (NPA) has raised concerns about the adequacy of funding. The association pointed out that the current deal does not fully address the rising costs facing pharmacies, including business rates, employer expenses, and the increasing price of medications. Dr Olivier Picard, chairman of the NPA, argued that the scheme remains “nowhere near ambitious enough to transform patient access to care” and that it fails to close the £2.5 billion funding gap the NHS identified a year ago.

“We remain concerned that it does very little to close the £2.5bn funding gap that the NHS itself identified a year ago,” Picard said. He warned that without sufficient resources, many pharmacies may struggle to implement the new changes, risking the scheme’s long-term success. “Pharmacies cannot sustain yet more loss-making work,” he added, highlighting the financial strain on the sector.

Dr Leyla Hannbeck, chief executive of the Independent Pharmacies Association, which represents over 5,000 pharmacies in England and Wales, echoed these sentiments. She noted that while the changes are “a step in the right direction,” the “funding on offer doesn’t cover the workload to do this.” Hannbeck described the situation as one where pharmacists are “really thinking about whether they can keep their heads above the water,” emphasizing the need for better financial support to ensure the scheme’s viability.

Regional Context and Future Implications

The Pharmacy First initiative in England is modeled after Scotland’s existing pharmacy-led healthcare system, which has been operating for some time. Northern Ireland and Wales also have frameworks allowing pharmacies to provide care for certain conditions, suggesting a shared vision across the UK for integrating pharmacists more deeply into primary healthcare.

With the new autumn additions, thousands of newly qualified pharmacists will enter the workforce, many of whom will have received training in prescribing as part of their professional development. This cohort will be instrumental in broadening the scope of the scheme and improving its effectiveness. However, the NPA’s concerns highlight a critical challenge: the expansion may not be sustainable without increased investment.

Pharmacists are increasingly being recognized as vital partners in the healthcare system, capable of managing chronic conditions, providing preventive care, and offering immediate treatment for minor ailments. The expanded role is seen as a way to optimize resource use and reduce delays in patient care. Yet, the financial pressures on the sector remain a key barrier to fully realizing this potential.

As the scheme progresses, its success will depend on a combination of factors: the adaptability of pharmacists, the effectiveness of new prescribing protocols, and the availability of adequate funding. The government has acknowledged the need for more support, but the debate over the extent of the investment continues. For now, the focus remains on rolling out the expanded prescriptions, with hopes that they will make a meaningful impact on healthcare accessibility and efficiency.

With the influx of trained pharmacists and the inclusion of new conditions, the Pharmacy First scheme could set a new standard for community-based care. However, the NPA’s warnings serve as a reminder that without addressing systemic financial challenges, the scheme may not achieve its full potential. The coming months will be crucial in determining whether this expansion translates into lasting improvements for patients and the healthcare system as a whole.

Experts suggest that the success of this model could influence future healthcare policies, potentially leading to greater collaboration between pharmacies and other healthcare professionals. As the NHS continues to evolve, the role of pharmacists is expected to grow, with the hope that their expanded responsibilities will contribute to a more responsive and patient-centered approach to care. The autumn rollout represents a pivotal moment in this transition, one that will be closely watched by stakeholders across the sector.